Search the Newsreel

How TG Therapeutics’ Q2 2026 Revenue Surge And Higher Guidance At TG Therapeutics (TGTX) Has Changed Its Investment Story

US Physical Therapy Appoints New Executive Vice President CFO

Zevra Therapeutics (ZVRA) insider files to resell RSU shares via broker

An insider at Zevra Therapeutics (ZVRA) has filed a Form 144 notice to resell up to 42,666 common shares. These shares are linked to restricted stock units granted in June 2025 and are planned for potential sale on NASDAQ. The filing also references previous …

Sarepta Stock Dips After Hours: DMD Drug Blow And CEO Exit Eclipse Q4 Revenue Beat

ALGS Stock Rallies 16% After-Hours On $25M Cash Boost From China Hepatitis B Drug Deal

What date does Scribe Therapeutics Inc.'s (SCTX) report Earnings - Earnings Calendar & Announcement

Saudi Fisheries Company Reports Earnings Results for the Second Quarter Ended June 30, 2026

TRAX Price Today: First Tracks Biotherapeutics, Inc. Stock Price, Quote & Chart | MEXC

This article provides current stock price information for First Tracks Biotherapeutics, Inc. (TRAX) on MEXC, detailing its live price, market data, and recent performance. It also includes instructions on how to buy TRAX on MEXC and offers a company overview, including its focus on …

Iovance Biotherapeutics, Inc. stock Analysis: 130% Rally & Overbought Signals 2026

Iovance Biotherapeutics, Inc. stock has rallied over 130% in 2026, closing at $6.98, but is showing strong overbought signals across multiple timeframes with daily RSI at 73.02. While the daily trend remains bullish due to strong EMA alignment and positive MACD, the elevated RSI …

Iovance Biotherapeutics, Inc. stock jumps 130% in 2026 but RSI screams overbought

HTZ|Hertz Global Holdings Inc|Price:2.240|Chg%:-0.105

After IOVA Stock’s Best Day In 2 Years, Analyst Sees Over 300% Upside: Here’s Why

BofA Securities Maintains Aardvark Therapeutics(AARD.US) With Sell Rating

BofA Securities has reiterated its Sell rating on Aardvark Therapeutics (AARD.US). The article does not provide further details regarding the financial implications or the analyst's rationale for maintaining this rating.

Corcept therapeutics chief development officer sells $1.8m in stock

William Guyer, Chief Development Officer at Corcept Therapeutics Inc. (NASDAQ:CORT), sold shares worth approximately $1.85 million on August 10, 2026, through two separate transactions under a 10b5-1 plan. Despite the sales, which occurred while the stock was near its 52-week high, Guyer also acquired …

Is Iovance Biotherapeutics (IOVA) Undervalued As Q2 Earnings Reaffirm Revenue Guidance?

Diluted earnings per share (diluted EPS) of Spero Therapeutics, Inc. – BMV:SPRO

Hershey Unwraps Biggest Halloween Lineup Yet As Spooky Season Starts Early

Hershey has announced its largest and most diverse Halloween lineup for 2026, launching it early due to increasing consumer demand for "Summerween" and early spooky season celebrations. The expanded portfolio includes returning favorites like Hershey's Cookies 'N' Creme Fangs, new Kit Kat and Reese's …

Relmada (RLMD) Q2 2026 Earnings Call Transcript

BMO Capital Initiates MapLight Therapeutics(MPLT.US) With Buy Rating, Announces Target Price $20

BMO Capital has initiated coverage on MapLight Therapeutics (MPLT.US) with a Buy rating and set a price target of $20. This indicates a positive outlook from the investment firm regarding the company's future stock performance.

Avalo Therapeutics CMO Mittie Doyle sells $13,580 in stock

Mittie Doyle, CMO at Avalo Therapeutics (NASDAQ:AVTX), sold 679 shares for $13,580 after exercising stock options under a Rule 10b5-1 trading plan. Following these transactions, she directly holds 51,776 shares and 114,413 stock options. This news follows Avalo's inclusion in the Russell 2000 and …

NTLA|Intellia Therapeutics Inc|Price:11.910|Chg%:+0.080

PTC Therapeutics Is Maintained at Overweight by Barclays

Barclays has reiterated its 'Overweight' rating on PTC Therapeutics (PTCT). The analyst firm maintained a price target of $70.00 for the company's stock. This indicates a positive outlook from Barclays regarding PTC Therapeutics' future performance.

Archer Aviation Shares Drop 5% After Boeing Agreement Puts $1 Billion Challenge Ahead

Why is Hims & Hers Health stock gaining today?

Nasdaq, S&P 500 Futures Edge Lower Ahead Of Fed Week, AI Earnings Test: Why POET, ATOM, OGN, QCOM, NTLA Are In Focus

HLS Therapeutics Inc. (TSE:HLS) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Is Herbalife’s Mixed Q2 Results and CFO Exit Altering The Investment Case For Herbalife (HLF)?

Outlook Therapeutics (OTLK) CFO Lawrence Kenyon buys 101K shares plus 101K warrants

Outlook Therapeutics' CFO, Lawrence A. Kenyon, purchased 101,010 shares of common stock and 101,010 accompanying warrants in an underwritten public offering on August 14, 2026. The combined offering price was $0.99 per share and warrant, with the warrants immediately exercisable at $1.10 and expiring …

Protagonist Therapeutics (NASDAQ:PTGX) Screens as an Affordable Growth Opportunity

Theravance Biopharma Deal Faces Investor Probe

Halper Sadeh LLC is investigating the proposed acquisition of Theravance Biopharma (NASDAQ: TBPH) by Zymeworks Inc. for $17 per share in cash plus a contingent value right. The investigation aims to determine if Theravance shareholders are receiving a fair price and if the company's …

XORTX Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Edgewise Therapeutics CEO Kevin Koch sells $785,042 in stock

Edgewise Therapeutics CEO Kevin Koch sold $785,042 worth of company stock on August 12, 2026, primarily to cover tax obligations related to Restricted Stock Unit vesting. Despite the sales, Mr. Koch also acquired new shares through vesting and was granted additional RSUs and stock …

Walleye Capital LLC Takes $1.59 Million Position in PTC Therapeutics, Inc. $PTCT

Walleye Capital LLC has acquired a new position in PTC Therapeutics, Inc., purchasing 19,522 shares valued at approximately $1.59 million during the second quarter. Several other institutional investors also increased their holdings in the biopharmaceutical company, which has an average analyst rating of "Moderate …

Weekly Recap: Sherwin-Williams & Valspar Paint Top This Week’s Stories

This article provides a weekly recap of the most-viewed news stories on Coatings World, highlighting key developments in the paint and coatings industry for the week ending August 15, 2026. Top stories include Sherwin-Williams' new ControlTech systems, Valspar Paint's Ready-Mix collection, and an interview …

LENZ Therapeutics (NASDAQ:LENZ) Stock Rating Upgraded by Zacks Research

Walleye Capital LLC Purchases New Shares in Kyverna Therapeutics, Inc. $KYTX